Scribe Therapeutics prices $128.7 million IPO at $15 per share

Scribe Therapeutics Inc. has set the terms of its initial public offering, offering 8,580,000 shares of its common stock at an initial public offering price of $15.00 per share.¹ This marks the company's initial public offering, with no public market currently existing for its common stock.¹ The total offering size is $128,700,000, with proceeds to the company before expenses estimated at $119,691,000 after underwriting discounts and commissions of $9,009,000.¹

The common stock has been approved for listing on the Nasdaq Global Market under the symbol "SCTX."¹ Underwriters have been granted a 30-day option to purchase up to 1,287,000 additional shares at the IPO price less underwriting discounts and commissions.¹

Separately, a Sanofi affiliate is participating in a related transaction. Aventis, Inc., a Sanofi company, together with Genzyme Corporation, Sanofi, has agreed to purchase 500,000 shares of common stock in a private placement outside the public offering, at the same $15.00 per share price.¹ That private placement is set to close alongside the IPO and depends on the IPO being completed, though the IPO itself does not depend on the private placement closing.¹

Underwriters expect to deliver shares to purchasers on or about July 27, 2026.¹ The lead underwriters are Leerink Partners, Goldman Sachs & Co. LLC, Guggenheim Securities, and Wells Fargo Securities.¹

Scribe's lead product candidate, STX-1150, utilizes ELXR, the company's epigenetic silencing technology, and is designed to deliver persistent and potent LDL-C reductions without permanent genetic changes.¹ The company has obtained regulatory clearance in Australia and begun dosing patients in a first-in-human study, described as evaluating STX-1150 in "up to 64 adults with elevated LDL-C and increased risk of ASCVD," according to the prospectus. Initial data on safety, tolerability, and LDL-C-lowering activity is expected in the first half of 2027.¹